Madrid

• A study to determine how BI 907828 (Brigimadlin) is taken up in the tumor (Phase 0) and to determine the highest dose of BI 907828 (Brigimad … Ended
  2023-506409-20-00 3 2023-11-24 Glioblastoma
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended
  2023-503418-63-00 4 2023-11-23 Head and Neck Squamous Cell Carcinoma
• AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEW … Ended
  2023-504545-31-00 1 2023-11-23 colorectal cancer
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• GRemubamab ErAdication Trial (GREAT-2) Ended
  2022-502494-41-00 4 2023-11-21 bronchiectasis and chronic Pseudomonas aeruginosa infection
• A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3) Ended
  2022-502881-25-00 4 2023-11-16 Hemophilia B
• A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended
  2022-502370-17-00 4 2023-11-14 Hidradenitis suppurativa
• A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moder … Ended
  2022-502880-39-00 4 2023-11-13 Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
• A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog … Ended
  2023-508458-25-00 10 2023-11-13 COVID-19 disease
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney trans … Ended
  2023-503951-81-00 4 2023-11-07 Respiratory Syncytial Virus Infections
• Randomised, crossover bioequivalence clinical trial of linagliptin 5 mg film-coated tablets, after a single oral dose administration to heal … Ended
  2023-506047-41-00 2 2023-11-07 diabetes
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended
  2022-503108-26-00 7 2023-11-06 Solid Tumor
• A prospective, multicentre open-label clinical trial to evaluate the efficacy of the fixed-dose combination of Doxylamine and Pyridoxine 10/ … Ended
  2023-505144-19-00 6 2023-10-31 Nausea and vomiting of pregnancy
• A Study to Evaluate Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED) Ended
  2022-502812-35-00 4 2023-10-26 Thyroid Eye Disease
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• A Study to Evaluate the Effect of BGF MDI, BFF MDI and Placebo MDI on Exercise Parameters in Participants with COPD Ended
  2022-502274-16-00 11 2023-10-19 Chronic Obstructive Pulmonary Disease
• A Study of NB003 in Patients With Advanced Malignancies Ended
  2022-502401-15-00 7 2023-10-19 Gastrointestinal stromal tumor
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer Ended
  2022-502125-17-00 1 2023-10-16 Advanced solid tumors
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended
  2022-501523-24-00 4 2023-10-12 Cutaneous Lupus Erythematosus (CLE)

Showing 2,881–2,904 of 3,550 trials